ArticleScientific reports2025
Assessment of the safety of hypoxia-primed mesenchymal stem cells derived from umbilical cord and adipose tissues in animals.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Recent trends in modified mesenchymal stromal cells: engineering approaches and international regulatory landscape.Molecular biology reports · 2026Review
- Treatment of Chronic Liver Fibrosis: Adipose and Bone Marrow Mesenchymal Stem Cells.International journal of molecular sciences · 2026Article
- Article
- Tissue factor and regenerative medicine: shaping cell and extracellular vesicle-based therapeutic approaches.Frontiers in cell and developmental biology · 2026Review
- Immunomodulatory properties of umbilical cord mesenchymal stromal cells in immune disorders: immunoregulatory functions, therapeutic progress, and engineering strategies for enhanced efficacy.Frontiers in immunology · 2026Review
- Safety evaluation of extracellular vesicles derived from hypoxia primed mesenchymal stem cells of umbilical cord and adipose tissue.Scientific reports · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
Mesenchymal stem cells (MSCs) are widely used for disease treatment, typically cultured in ambient oxygen (21%) exceeding physiological levels (2-5%). While hypoxic MSCs show in vitro advantages, their in vivo effects remain less understood. This study evaluated the safety of xeno-free, serum-free cultured MSCs from adipose tissue (AD-MSCs) and umbilical cords (UC-MSCs) primed with 5% oxygen in healthy rabbits, Swiss mice, and rats. Assessments included vascular and muscle stimulation, systemic hypersensitivity, acute toxicity, and subchronic toxicity. Our data indicated that the injection of UC-MSCs induced vascular stimulation but not muscular stimulation, whereas the injection of AD-MSCs caused neither vascular nor muscular stimulation. Additionally, neither AD-MSCs nor UC-MSCs affected hematopoietic parameters (white blood cell, red blood cell, platelet, or hemoglobin levels), altered the levels of proinflammatory cytokines (IL-6, IL-1β, IFN-γ, and TNF-a), or induced allergenic responses in rabbits. Furthermore, intravenous injection of either UC-MSCs or AD-MSCs at a dose of 50 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.